All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Treatment of thrombotic complications in patients with MPN
Bookmark this article
|
Thrombotic events represent the most significant complications in patients with MPN, with a primary treatment goal of reducing their frequency and reccurrence.1 In current clinical practice, patients with either a history of thrombosis or aged ≥60 years are classed as high thrombotic risk and managed with cytoreductive treatment.1 More precise thrombotic risk evaluation may be feasible using other factors, such as the presence of a high (>1%) JAK2V617F allele burden.1
|
| Key learnings |
| Cytoreductive and anti-thrombotic agents are complementary for thrombotic risk reduction. Long-term anti-thrombotic strategies should be tailored to the initial thrombosis type, MPN subtype, and bleeding risk. |
| Antiplatelet therapy or revascularization may be required, with indefinite low-dose aspirin recommended following initial therapy after some thrombotic events. |
| Regular re-evaluation of the risk/benefit balance of continued antithrombotic treatment in MPN patients treated with anticoagulants is important for improving patient outcomes. |
| Patients with MPN and thrombosis should be cared for in multidisciplinary settings to ensure the provision of optimal individualized treatment strategies. |
Abbreviations: MPN, myeloproliferative neoplasms; SVT, splanchnic vein thrombosis.
- Guy A, Morange P, James C. How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms. Blood 2024;blood.2024025627.
Related articles
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Nov 30, 2023
Thrombotic and hemorrhagic complications in MPN
Thrombotic and hemorrhagic complications in MPN
Nov 30, 2023
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox